Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of study by passing a written examination prior to vaccination.~* In the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).~* Written informed consent obtained from the subject prior to performance of any study specific procedure.~* Male or non-pregnant female between, and including, 18 and 39 years of age at the time of the first vaccination.~* Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality\*.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential must have a negative pregnancy test within 24 hours of vaccination.~* Female subjects of childbearing potential must have practiced adequate contraception for 30 days prior to first vaccination and agree to continue adequate contraception until 2 months after completion of the vaccination series (Month 5).~* Male subjects must be surgically sterile (e.g., vasectomy) or agree to practice adequate contraception from the first vaccination until 2 months after completion of the vaccination series (Month 5). Please refer to the glossary of terms for the definition of adequate contraception.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines.~* Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.~* Medically diagnosed deviated nasal septum or nasal obstruction.~* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within 6 months before the first dose.~* Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months before the first dose (Visit 03), or planned administration any time during the study period.~* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose (Visit 03) up to Month 15 (Visit 15)~* Persons who should be annually vaccinated against influenza who live with or care for persons at high risk for influenza-related complications.~* History of influenza vaccination within 6 months prior to study enrollment or unwillingness to forego seasonal influenza vaccination during the entire study period.~* History of vaccination with an investigational pandemic influenza vaccine other than an 2009 H1N1 Pandemic (H1N1pdm09) vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Infection with human immunodeficiency virus regardless of clinical stage of immunodeficiency.~* History of current infection with hepatitis B virus or hepatitis C virus regardless of clinical presentation.~* History of or current autoimmune disease.~* Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling.~* History of Guillain-Barré syndrome.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including egg proteins); a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.~* Hypersensitivity to latex.~* Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.~* Pregnant or lactating female.~* Female planning to become pregnant or male planning to father a child or either planning to discontinue contraceptive precautions.~* Current smoker.~* During screening, have a positive test for opiates without a prescription.~* History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.~* Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with subject compliance or safety evaluations.~* Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 10 years prior to study vaccination.~* Blood donation or planned blood donation within 30 days prior to the study vaccination through 30 days after the last blood drawn for this study.~* Have signs or symptoms that could confound or confuse assessment of study vaccine reactogenicity.~* Any hematological or biochemical parameter that is out of range of normal, and is considered clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant (Type: EXPERIMENTAL): Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
- Group 2: cH8/1N1 LAIV and cH5/1N1 IIV (Type: EXPERIMENTAL): Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
- Group 3: Placebo (Type: PLACEBO_COMPARATOR): Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
- Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant (Type: EXPERIMENTAL): Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
- Group 5: Placebo (Type: PLACEBO_COMPARATOR): Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.

Based on this trial design, predict the completion outcome and termination type (if applicable).